Multicenter Registration Study on Allergic Bronchopulmonary Aspergillosis

Not yet recruiting

• Conditions: Allergic Bronchopulmonary Aspergillosis

• Registration Number: NCT06645210
• Lead Sponsor: Peking University Third Hospital

Brief Summary

To understand the current diagnosis and treatment status of ABPA patients, observe their clinical characteristics, prognosis, and treatment outcomes, and identify the relevant factors for poor prognosis in patients.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Status Verified: 2024-10
• Study First Submitted: 2024-10-11
• Study Start: 2024-10-15
• Study First Submitted QC: 2024-10-15
• Last Update Submitted: 2024-10-15
• Study First Posted: 2024-10-16
• Last Update Posted: 2024-10-16
• Primary Completion: 2025-12-31
• Study Completion: 2026-01-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Meeting the diagnosis of ABPA according to the ABPA diagnostic criteria specified by the ISHAM-ABPA working group in 2024

Read More

Exclusion Criteria

ABPA patients who are not first diagnosed in the center

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical classification and treatment response criteria for ABPA	1 year	1. Acute ABPA; 2. Response; 3. Remission; 4. Treatment-dependent ABPA; 5. Advanced ABPA

Trial Locations

Locations (1)

Peking University Third Hospital; 🇨🇳 Beijing, Beijing, China